Jade Heinen, MD
Family Medicine · Eunice, LANPI 1174732424
Payments from drug & device makers
Across 240 payments — averaging $15.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$880
- GSK$783
- Pfizer$329
- Novo Nordisk$196
- Getinge USA Sales, LLC$140
- Ardelyx, Inc.$125
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,686100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 60 | $880 |
| GSK | 58 | $783 |
| Pfizer | 21 | $329 |
| Novo Nordisk | 13 | $196 |
| Getinge USA Sales, LLC | 5 | $140 |
| Ardelyx, Inc. | 7 | $125 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $122 |
| AstraZeneca | 6 | $103 |
| Currax Pharmaceuticals LLC | 7 | $100 |
| Dexcom, Inc. | 5 | $93 |
| Exact Sciences | 5 | $85 |
| Lilly USA, LLC | 6 | $83 |
| Abbott | 5 | $76 |
| Novartis | 5 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $52 |
| Nalpropion Pharmaceuticals LLC | 2 | $48 |
| Boehringer Ingelheim | 3 | $43 |
| Amgen | 3 | $35 |
| Lundbeck LLC | 2 | $34 |
| Axsome Therapeutics, Inc. | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Zyla Life Sciences, Inc. | 2 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $25 |
| Silk Road Medical, Inc. | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Vifor Pharma, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Corcept Therapeutics | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
How this compares
$3,686 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 90 | $94,803 |
| MounjaroTirzepatide | 74 | $80,630 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 73 | $48,084 |
| LinzessLinaclotide | 58 | $36,362 |
| EliquisApixaban | 47 | $26,874 |
| EntrestoSacubitril/Valsartan | 22 | $16,029 |
| XareltoRivaroxaban | 14 | $15,682 |
| JardianceEmpagliflozin | 29 | $14,631 |
| MyrbetriqMirabegron | 24 | $11,668 |
| FarxigaDapagliflozin Propanediol | 14 | $11,472 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $8,506 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $8,034 |
| Repatha SureclickEvolocumab | 14 | $7,911 |
| Repatha SyringeEvolocumab | 12 | $6,919 |
| JanuviaSitagliptin Phosphate | 17 | $5,990 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $196 | $94,80390 claims |
| Lilly USA, LLCMounjaro | $83 | $80,63074 claims |
| GSKTrelegy Ellipta | $783 | $48,08473 claims |
| AbbVieLinzess | $880 | $36,36258 claims |
| PfizerEliquis | $329 | $26,87447 claims |
| AstraZenecaFarxiga, Symbicort | $103 | $16,16327 claims |
| NovartisEntresto | $71 | $16,02922 claims |
| Boehringer IngelheimJardiance | $43 | $14,63129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Eunice
- David WareEunice$29K
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.